A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
Sponsor: Genmab A/S
Phase: 3
Disease: RAS/BRAF wild-type unresectable or metastatic left-sided colorectal adenocarcinoma
EU trial number: 2026-525883-17-00
Population: Adults with previously untreated unresectable or metastatic left-sided colorectal adenocarcinoma with confirmed wild-type KRAS, NRAS and BRAF, and no prior EGFR-directed therapy; randomized to petosemtamab or cetuximab each combined with investigator-selected mFOLFOX6 or FOLFIRI chemotherapy.
Register Investigator Interest
Interested in offering this trial to suitable patients?